Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs